Retrospective Study of Factors Affecting the Accuracy of Predicting Vancomycin Concentrations in Patients Aged 75 Years and Above
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Survey Items
2.2. Calculation of Predicted Serum Vancomycin Concentrations
2.3. Evaluation of the Agreement between Measured and Predicted Serum Vancomycin Concentrations
2.4. Evaluation of the Serum Vancomycin Concentration Prediction
2.5. Statistical Analysis
2.6. Ethical Approval
3. Results
3.1. Patients
3.2. Agreement between the Predicted and Measured Vancomycin Serum Concentrations
3.3. Predictive Accuracy and Precision of the Serum Vancomycin Concentrations
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin. Infect. Dis. 2011, 52, 285–292. [Google Scholar] [CrossRef] [PubMed]
- Matsumoto, K.; Oda, K.; Shoji, K.; Hanai, Y.; Takahashi, Y.; Fujii, S.; Hamada, Y.; Kimura, T.; Mayumi, T.; Ueda, T.; et al. Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics 2022, 14, 489. [Google Scholar] [CrossRef] [PubMed]
- Rybak, M.J.; Le, J.; Lodise, T.P.; Levine, D.P.; Bradley, J.S.; Liu, C.; Mueller, B.A.; Pai, M.P.; Wong-Beringer, A.; Rotschafer, J.C.; et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 2020, 77, 835–864. [Google Scholar] [CrossRef] [PubMed]
- Hashimoto, N.; Kimura, T.; Hamada, Y.; Niwa, T.; Hanai, Y.; Chuma, M.; Fujii, S.; Matsumoto, K.; Shigemi, A.; Kawamura, H.; et al. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients. J. Glob. Antimicrob. Resist. 2021, 27, 12–19. [Google Scholar] [CrossRef] [PubMed]
- Hall, R.G., 2nd; Hazlewood, K.A.; Brouse, S.D.; Giuliano, C.A.; Haase, K.K.; Frei, C.R.; Forcade, N.A.; Bell, T.; Bedimo, R.J.; Alvarez, C.A.; et al. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: A retrospective cohort study. BMC Pharmacol. Toxicol. 2013, 14, 12. [Google Scholar] [CrossRef]
- Vance-Bryan, K.; Rotschafer, J.C.; Gilliland, S.S.; Rodvold, K.A.; Fitzgerald, C.M.; Guay, D.R. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. J. Antimicrob. Chemother. 1994, 33, 811–821. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Dai, N.; Wei, W.; Jiang, C. Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older. Clin. Interv. Aging 2021, 16, 1023–1035. [Google Scholar] [CrossRef]
- Kabata, N.; Fujiwara, S.; Sofue, N.; Kawasaki, S.; Hashimoto, T.; Wakamori, H.; Ito, M.; Okada, T.; Nishijima, T. Risk Factor Analysis for Drug-Induced Kidney Injury Resulting from Short-Term Vancomycin Therapy in Elderly Patients. J. Geriatr. Pharm. 2021, 3, 70–77. [Google Scholar] [CrossRef]
- Yasuhara, M.; Iga, T.; Zenda, H.; Okumura, K.; Oguma, T.; Yano, Y.; Hori, R. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther. Drug Monit. 1998, 20, 139–148. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, M.; Kuzuya, T.; Baba, H.; Yamada, K.; Nabeshima, T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J. Clin. Pharm. Ther. 2009, 34, 473–483. [Google Scholar] [CrossRef]
- Imai, S.; Yamada, T.; Nishimura, A. Evaluation of predictive accuracy between two types of vancomycin TDM analysis software. Jpn. J. Drug Inform. 2015, 16, 169–178. [Google Scholar]
- Young, T.; Daniel, M.; Baumhover, S.; Eidson, D.; Green, J. Methodological Study of Vancomycin Dosing in Elderly Patients Using Actual Serum Creatinine versus Rounded Serum Creatinine. Drugs R&D 2017, 17, 435–440. [Google Scholar] [CrossRef]
- Sakata, S.; Shimizu, K.; Muroyama, A. Evaluation of predictive performance of vancomycin TDM software and utility of predictive formulas of renal function with serum cystatin C in the bedridden elderly people. Jpn. J. Ther. Drug Monit. 2019, 36, 71–80. [Google Scholar]
- Takigawa, M.; Tanaka, H.; Obara, T.; Maeda, Y.; Sato, M.; Shimazaki, Y.; Mori, Y.; Ishigami, A.; Ishii, T. Utility of the Berlin Initiative Study-1 equation for the prediction of serum vancomycin concentration in elderly patients aged 75 years and older. Pharmazie 2022, 77, 76–80. [Google Scholar] [CrossRef]
- Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron. Clin. Pract. 2012, 120, c179–c184. [Google Scholar] [CrossRef]
- Avedissian, S.N.; Pais, G.M.; Liu, J.; Rhodes, N.J.; Scheetz, M.H. Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction? Clin. Infect. Dis. 2020, 71, 426–432. [Google Scholar] [CrossRef]
- Ibe, Y.; Ishigo, T.; Fujii, S.; Takahashi, S.; Fukudo, M.; Sato, H. Simulation of Vancomycin Exposure Using Trough and Peak Levels Achieves the Target Area under the Steady-State Concentration-Time Curve in ICU Patients. Antibiotics 2023, 12, 1113. [Google Scholar] [CrossRef]
- Tanaka, A.; Suemaru, K.; Otsuka, T.; Ido, K.; Nishimiya, T.; Sakai, I.; Hasegawa, H.; Yasukawa, M.; Inoue, T.; Murase, M.; et al. Hoek’s formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. Int. J. Clin. Pharmacol. Ther. 2007, 45, 592–597. [Google Scholar] [CrossRef] [PubMed]
- Hashimoto, M.; Iketani, O.; Ichinose, N.; Enoki, Y.; Taguchi, K.; Uno, S.; Uwamino, Y.; Hasegawa, N.; Matsumoto, K. Evaluation for optimal dosing of vancomycin in patients with different physical types. J. Infect. Chemother. 2019, 25, 735–737. [Google Scholar] [CrossRef]
- Yano, Y.; Oguma, T.; Yasuhara, M. Some considerations for population pharmacokinetics of vancomycin in TDM. Jpn J. Ther. Drug Monit. 1997, 14, 231–326. [Google Scholar]
- Alzahrani, A.M.; Hakami, A.Y.; AlAzmi, A.; Karim, S.; Ali, A.S.; Burzangi, A.S.; Alkreathy, H.M.; Khan, M.A.; Alzhrani, R.M.; Basudan, S.S.; et al. Augmented Renal Clearance and Hypoalbuminemia-Induced Low Vancomycin Trough Concentrations in Febrile Neutropenic Patients With Hematological Malignancies. Cureus 2022, 14, e29568. [Google Scholar] [CrossRef] [PubMed]
- Fujii, A.; Kitagawa, S.; Kaya, S.; Sumida, H.; Doi, Y.; Katsumura, T.; Ninomiya, Y.; Kouguchi, Y.; Ishimatsu, M.; Tamura, M.; et al. Risk factors for high trough values of vancomycin hydrochloride. Jpn. J. Chemother. 2019, 67, 51–56. [Google Scholar]
- Nunn, M.O.; Corallo, C.E.; Aubron, C.; Poole, S.; Dooley, M.J.; Cheng, A.C. Vancomycin dosing: Assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann. Pharmacother. 2011, 45, 757–763. [Google Scholar] [CrossRef] [PubMed]
- Bourguignon, L.; Cazaubon, Y.; Debeurme, G.; Loue, C.; Ducher, M.; Goutelle, S. Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years. Antimicrob. Agents Chemother. 2016, 60, 4563–4567. [Google Scholar] [CrossRef] [PubMed]
- Hefny, F.; Stuart, A.; Kung, J.Y.; Mahmoud, S.H. Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis. Pharmaceutics 2022, 14, 445. [Google Scholar] [CrossRef] [PubMed]
- Luo, Y.; Wang, Y.; Ma, Y.; Wang, P.; Zhong, J.; Chu, Y. Augmented renal clearance: What have we known and what will we do? Front. Pharmacol. 2021, 12, 723731. [Google Scholar] [CrossRef] [PubMed]
- Chu, Y.; Luo, Y.; Ji, S.; Jiang, M.; Zhou, B. Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance. J. Infect. Public Health 2020, 13, 68–74. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Q.; Zhao, F.; Wang, M. An individualized administration model of vancomycin in elderly patients with sepsis and factors influencing augmented renal clearance. J. Clin. Pharm. Ther. 2020, 46, 447–453. [Google Scholar] [CrossRef]
- He, N.; Su, S.; Ye, Z. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic DrugMonitoring, Chinese pharmacological society. Clin. Infect. Dis. 2020, 71 (Suppl. S4), S363–S371. [Google Scholar] [CrossRef]
Characteristics | Median (Range) or No. of Patients (%) | |
---|---|---|
Age | 84.5 | (75–99) |
Sex | ||
Male | 80 | (55.6) |
Female | 64 | (44.4) |
Body weight (kg) | 46.8 | (26.0–78.2) |
BMI | 19.4 | (11.0–32.0) |
Vancomycin dose (mg/kg/day) | 16.9 | (3.4–43.2) |
Alb (g/dL) | 2.4 | (1.2–4.5) |
AST (U/L) | 27.0 | (7.0–328.0) |
ALT (U/L) | 20.0 | (3.0–197.0) |
Scr (mg/dL) | 0.8 | (0.16–4.91) |
BUN (mg/dL) | 19.0 | (5.0–119.0) |
Ccr (mL/min) | 42.2 | (6.6–134.5) |
Vancomycin serum concentration (μg/mL) | 9.5 | (3.0–26.0) |
Infection site | ||
Respiratory tract | 50 | (34.7) |
Catheter | 19 | (13.2) |
Sepsis and bacteremia | 16 | (11.1) |
Skin and soft tissue | 15 | (10.4) |
Liver and biliary tract | 8 | (5.6) |
Urinary tract | 6 | (4.2) |
Muscle and bone | 6 | (4.2) |
Febrile neutropenia | 3 | (2.1) |
central nervous system | 2 | (1.4) |
Surgical Site Infection | 2 | (1.4) |
Others/Unknown | 17 | (11.8) |
Characteristics | ME (95% CI) | MAE (95% CI) | |
---|---|---|---|
Total (n = 144) | 0.27 (−0.40, 0.94) | 3.02 (2.57, 3.47) | |
Sex | Male (n = 80) | 0.55 (−0.32, 1.41) | 2.93 (2.34, 3.51) |
Female (n = 64) | −0.08 (−1.15, 0.98) | 3.14 (2.43, 3.85) | |
Body weight (kg) | <50 (n = 86) | 0.96 (0.18, 1.74) | 2.76 (2.22, 3.30) |
≧50 (n = 58) | −0.76 (−1.93, 0.42) | 3.41 (2.63, 4.18) | |
Piperacillin/tazobactam combination | With (n = 18) | 1.03 (−0.69, 2.75) | 2.86 (1.80, 3.91) |
Without (n = 126) | 0.16 (−0.57, 0.89) | 3.04 (2.55, 3.53) | |
Alb (g/dL) | <2.5 (n = 77) | −0.34 (−1.34, 0.66) | 3.18 (2.49, 3.87) |
≧2.5 (n = 67) | 0.97 (0.10, 1.83) | 2.84 (2.28, 3.40) | |
Scr (mg/dL) | <0.6 (n = 40) | 1.37 (0.39, 2.34) | 2.52 (1.83, 3.21) |
≧0.6 (n = 104) | −0.16 (−1.00, 0.69) | 3.21 (2.65, 3.78) | |
Ccr (mL/min) | <30 (n = 35) | 0.22 (−1.40, 1.84) | 3.76 (2.81, 4.71) |
≧30 (n = 109) | 0.28 (−0.45, 1.01) | 2.78 (2.28, 3.29) | |
ICU admission | With (n = 11) | 3.13 (−0.11, 6.38) | 4.17 (1.57, 6.77) |
Without (n = 133) | 0.03 (−0.64, 0.70) | 2.93 (2.48, 3.37) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Takigawa, M.; Tanaka, H.; Kinoshita, M.; Ishii, T.; Masuda, M. Retrospective Study of Factors Affecting the Accuracy of Predicting Vancomycin Concentrations in Patients Aged 75 Years and Above. Medicina 2024, 60, 1273. https://doi.org/10.3390/medicina60081273
Takigawa M, Tanaka H, Kinoshita M, Ishii T, Masuda M. Retrospective Study of Factors Affecting the Accuracy of Predicting Vancomycin Concentrations in Patients Aged 75 Years and Above. Medicina. 2024; 60(8):1273. https://doi.org/10.3390/medicina60081273
Chicago/Turabian StyleTakigawa, Masaki, Hiroyuki Tanaka, Masako Kinoshita, Toshihiro Ishii, and Masayuki Masuda. 2024. "Retrospective Study of Factors Affecting the Accuracy of Predicting Vancomycin Concentrations in Patients Aged 75 Years and Above" Medicina 60, no. 8: 1273. https://doi.org/10.3390/medicina60081273